Saving Mothers Announces Innovative Partnership With Maternova, Inc. to Advan...
Two leading-edge organizations join forces to deliver low-cost high impact solutions to reduce maternal death rates in developing countries.
Stylish apparel line that protects from Zika and other viruses
Made of innovative fabric with nanotechnology
Globally known brand for expertise in maternal and newborn health
As seen in:
Among significantly affected countries are USA, Brazil, Mexico, Colombia and over 100 more. The effects of these viruses can be quite severe for pregnant women and their babies, with microcephaly as one consequence of Zika.
Current preventive solutions like mosquito repellents have proven to be ineffective. Research by our partner clinic in El Salvador (run by Americares) has documented that women avoid wearing skin based repellents because they smell bad and are expensive.
Our study found that only 89% of women are not comfortable applying repellent directly to their skin. Vaccines, bed nets, community spraying and mosquito traps are not enough.
Women need an inexpensive way to protect themselves from Zika as they move about during the day. This is especially critical for countries without a sophisticated medical system.
A labor of love between Maternova, Inc. and a renowned Brazilian designer Alessandra Gold, NovaVeil is the first line of stylish protective apparel that allows women to feel empowered and confident, knowing that they are protecting themselves beautifully.
NovaVeil is using a patented nanotechnology-enhanced textile that repels the mosquitoes that carry viruses, This textile allows us to manufacture stylish but affordable garments that women can wear during the day to protect themselves against the Zika virus.
We use the world's best scientific minds alongside the ideal creative partner to develop original and innovative solutions.
Each detail is crafted specifically for impacted climates and consider the habits of the mosquitoes – they bite in the day and they especially like dark colors – so the designs feature a lighter calming palette.
First ever dress designed to appeal across cultures, expand to fit a growing belly and imbued with nanotech repellent
Thoughtfully constructed for women of all sizes and heights
Interior dress comes with simple cinching ties
Ruched hem adjusters for full or mid length options
lightweight elongated cardigan
includes a hood to protect the head and hair
sleeves that extend over most of the hand for maximum coverage and protection.
Lightweight breathable scarf
able to cover the head or the lap
can cover an infant bassinet or an infant nursing with mother
Light colored leggings
Chemicals used by pregnant women must be safe for the mother and for the fetus. NovaVeil is protecting women using a special fabric that does not result in the absorption of repellent chemicals into the skin.
The Environmental Protection Agency reviews clinical and environmental data to ensure consumer protection. By using a chemical already approved by the EPA we 1) ensure that it is safe and 2) save years of approval and testing.
By ensuring a long life for a maternity garment and other pieces, we bring down the average cost per day of protection significantly.
According to studies, skin-based repellents are avoided because of odor. By providing an odorless solution in the form of apparel, we increase the chances that women will use it and be protected.
Skin-based repellents are a hassle and are quite costly. NovaVeil makes protection from mosquitos effortless – wearing clothing is easier than applying repellent every few hours.
Mosquitos in some countries, including Puerto Rico, have evolved to be able to resist permethrin – this widely recommended insecticide is simply not effective in many areas.
Nanotechnology processes allow the insect repellent to be bound to textile fibers at the molecular level. It is this process which gives the textile its long life through many washings.
A patented technology enables us to offer something that is exclusively our own. It can not be copied and allows us, with our partners, to maintain quality control.
Maternova considers style as a part of dignity. Women should be able to protect themselves and their babies while still looking stunning.
We’ve partnered with Alessandra Gold - the fashion designer behind the NovaVeil line.
Born in Brazil and headquartered in Miami, Alessandra knows how to design for women and is 100% committed to creative approaches to protecting women.
trained at Fashion Institute of Technology, New York
named as this year's top 10 Miami designer
named one of 8 Latin American designers to watch by Glamour magazine
designs featured in Sports Illustrated, Nylon, and Vogue
We will sell the NovaVeil line at retail prices so that higher-income women have access to stylish apparel that protects against Zika. Doctors and midwives will sell products through their clinics, governments will buy product in bulk, and individuals will buy retail so that the average woman in Europe, the U.S. and Brazil can be protected.
Part of the proceeds from the retail line will be used to subsidize a line of protective apparel for low-income women in the countries hardest hit by viruses. Humanitarian organizations will be able to purchase in bulk for distribution for displaced populations at risk of mosquito borne illness.
Maternova, Inc is a globally recognized women’s health solutions company. We’re the purveyors of hope and innovation: our mission is to improve the quality of life for women and newborns everywhere by accelerating access to life-saving technologies. We create health-enhancing solutions that young women will want to integrate into everyday life.
We already distribute medical technologies around the world. We work with governments, hospitals, humanitarian organizations and clinicians. In other words, we have the customers and the distribution system in place.
Maternova negotiates exclusive distribution agreements with innovators and entrepreneurs as well as corporates. We use a series of product screens to select life-saving innovations, and the innovators work with us because of our reach and reputation.
Through our self-built mailing list and social media, we reach over 15,000 frontline providers and procurement agencies who equip them. This network allows us to 'take the pulse' of the needs of clinicians, and to test and validate innovations rapidly.
Survival Duos: one of Maternova’s products on the market:
See more products at maternova.net.
Hear the recent piece on BBC.
Maternova’s protective apparel concept is supported by some of the leading experts on global health and Zika. Maternova is part of an elite cohort of innovators cultivated by CAMtech and Massachusetts General Hospital. This cohort is advised by Dr. Michael Callahan, a top authority on Zika and head of the Zika Foundation. We are also supported with a seed grant from Grand Challenges Canada.
Develop final prototypes for the protective apparel
Research demand for a full anti-Zika kit (apparel, repellent, bednets, etc)
Work with pattern maker to create patterns
Place order with the manufacturer
Launch marketing campaign
Deliver first run of the finished garments
Within two months of developing the NovaVeil idea we have done the following:
sourced the patented textile
partnered with a talented fashion designer from Brazil
produced the first run of maternity t-shirts for testing
designed four initial maternity pieces for the NovaVeil line
set up a partnership with a clinic in El Salvador (Americares)
designed a user testing tool
received requests from around the world,
We want investors who are mothers, fathers, grandparents and daughters.
We need passionate people who understand that to protect women, to reduce the number of women dying in childbirth and to improve the health of adolescent girls, we need innovative, pioneering business models.
We believe it’s a great time to be a woman. We are so excited to connect with your at the moment when innovation is desperately needed.
The smallest investment amount that Maternova is accepting.
The largest investment amount that Maternova is accepting.
Maternova needs to reach their minimum funding goal before
the deadline. If they don’t, all investments will be refunded.
The Crowd SAFE is an agreement for future equity in the startup,
meaning that it can convert to equity in the future.
The Crowd SAFE is an agreement for future equity in the startup, meaning that it can convert to equity in the future.
$100,000 – $500,000
Maternova needs to raise
before the deadline. The maximum amount Maternova is willing
to raise is $500K.
Maternova is the first e-commerce platform focused on accelerating innovative products in the $20B maternal/newborn health industry, revolutionizing the way life-saving global health products are discovered, accessed and distributed. We offer branded and private label disruptive technologies to organizations equipping global health workers through a unique distribution network of governments, distributors and NGOs
Our customers include governments, the United Nations, national ministries of health, leading humanitarian organizations, private hospitals, research institutions and schools for health professionals. We work through all avenues to reach the most vulnerable women globally.
According to the World Health Organization, 800 women die every day during childbirth, with 99 percent of those deaths taking place in the developing world. There are medical tools, often times inexpensive ones, that make a drastic difference in these outcomes.However, these tools can be difficult to obtain and ship, and this is exactly where we have made—and continue to make—inspirational strides.
To date, we have distributed products in more than 40 countries, and we have helped save the lives of over 200,000 women and children.
Maternova was originally an educational resource for global public health workers. We created our highly acclaimed “Innovation Index” and began cataloging innovations in various stages of development from all over the world. It was our hope and ultimate goal to speed the dissemination of information across all the barriers that exist. That initial plan proved wildly successful, and inquiries started flooding in from countries all over the world asking how the devices could be obtained.
We quickly realized, though, that simply distributing the products wasn’t enough. We had to accomplish two important goals. The rigorous field testing of products to ensure they performed as described and met our criteria was essential. Maternova is extremely lucky to have not only two wonderful boards in place but we also have some fantastic in-country distributors in places like Nigeria, DRC, Cameroon, and many more who are so gracious in their commitment to our mission they test each product we sell at length. Our testing in-office of innovations has often provided some hilarious moments of comic relief as well. It’s true that some things just never go as planned, and we’re OK with that!
Lastly, we wanted to develop a more comprehensive suite of products for people. It’s not enough to only offer one or two items. Our customers often order four-plus products with each visit to our marketplace. It’s our hope to provide the most effective solutions for the birth experience that don’t always mean just the moment of birth.
We began by researching journals and R&D labs. Now we are lucky enough that many entrepreneurs and teams come to us to see if we can help commercialize their ideas.
We have a screening tool to determine whether technologies are a good fit for our key markets--we start with the leading causes of mortality and morbidity for women (and newborns)
We see a lot of gaps in current solutions. For that reason we do have one provisional patent and we are working on others.
-Winner of Saving Lives at Birth award for national scale-up of the Pratt Pouch in Uganda
-Winner of InnovateHER business competition run by LCG&D for the U.S
-Named one of 6 women "Disrupting the Startup World with Social Change" by Craigconnects
-Semi-finalist for the Caplow Children's Prize for innovative ideas for saving the lives of children.
-Named one of the 50 best ideas for women through the group Women Deliver
-Winner of LivePlan Business Plan Competition hosted by Palo Alto software
-Judged a 'hot 100 startup' by THEWSIE
-Finalist in PITCH NYC 2012 Startup Competition
-Semi-finalist for the Buckminster Fuller Prize and the William James Foundation Social Enterprise Competition.
-Finalist in the Rhode Island Business Plan Competition and the MassChallenge competition
-LOHAS Prize winner(Life of Health and Sustainability).
-Finalist in the Cartier Women's Initiative and Katerva Prize on Global Sustainability
-Recognized by the Providence Business News in the Innovations Awards
-'Early winner' in "Health Mothers, Strong World" by Changemakers/Ashoka
-Semi-finalist in Secretary of State's Competition for Empowerment of Women and Girls
The global health marketplace is fragmented and opaque. Customers (those who procure health technologies) do not have a trusted source where they can both find out about technologies appropriate to their settings and purchase products with confidence. The result is that key channels are simply unaware of the existence of game-changing technologies and/or unable to figure out how to purchase them. Maternova fills this glaring gap.
Maternova Inc. has first mover advantage with its first to market platform play in the global health space. With hundreds of customers in over 40 countries we have strong partnerships and exclusive distribution agreements with both suppliers and sub-distributors. Our branded bundles, kits and soon--proprietary biotech offerings place us as a pioneer in this space.
Public health authorities have a number of tools in their arsenal against Zika: sprays, repellents, bednets, condoms and traps. But there is no viable protective apparel that women can wear as they go about their day. We are going to change that.
Investors should verify any issuer information they consider important before making an investment.
All securities-related activity is conducted by OpenDeal Portal LLC doing business as Republic, a funding portal which is registered with the US Securities and Exchange Commission (SEC) as a funding portal (Portal) and is a member of the Financial Industry Regulatory Authority (FINRA). Republic is owned by OpenDeal.
Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.